Cytosorbents (NASDAQ:CTSO) Share Price Crosses Above 200 Day Moving Average - Time to Sell?

Cytosorbents Corporation (NASDAQ:CTSO - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.01 and traded as high as $1.37. Cytosorbents shares last traded at $1.26, with a volume of 210,583 shares.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Wall Street Zen began coverage on Cytosorbents in a report on Wednesday, May 21st. They set a "hold" rating for the company. D. Boral Capital reissued a "buy" rating and issued a $10.00 price target on shares of Cytosorbents in a research report on Wednesday. Finally, HC Wainwright restated a "neutral" rating and set a $1.00 price objective on shares of Cytosorbents in a report on Thursday, May 15th.

Cytosorbents Stock Performance

The firm has a market cap of $77.01 million, a P/E ratio of -4.39 and a beta of 1.05. The company has a current ratio of 2.61, a quick ratio of 2.30 and a debt-to-equity ratio of 0.98. The company's 50-day moving average is $1.00 and its two-hundred day moving average is $1.01.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The medical research company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02. The company had revenue of $8.73 million for the quarter, compared to analyst estimates of $9.01 million. Cytosorbents had a negative net margin of 41.77% and a negative return on equity of 105.04%. As a group, equities analysts predict that Cytosorbents Corporation will post -0.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CTSO. Millennium Management LLC bought a new stake in shares of Cytosorbents during the 4th quarter worth $30,000. Goldman Sachs Group Inc. increased its holdings in Cytosorbents by 149.2% during the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company's stock worth $63,000 after buying an additional 37,519 shares during the last quarter. Key Client Fiduciary Advisors LLC raised its position in Cytosorbents by 127.0% in the first quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company's stock worth $78,000 after acquiring an additional 43,900 shares during the period. Renaissance Technologies LLC raised its position in Cytosorbents by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company's stock worth $80,000 after acquiring an additional 8,400 shares during the period. Finally, Northern Trust Corp boosted its stake in Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock valued at $83,000 after acquiring an additional 16,701 shares during the last quarter. Institutional investors own 32.87% of the company's stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.